<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oncology Product Guide &#187; clinical trial</title>
	<atom:link href="http://www.oncologyproductguide.com/blog/tag/clinical-trial/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.oncologyproductguide.com/blog</link>
	<description>A comprehensive guide to oncology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:00:01 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Novartis kidney cancer drug shows promise</title>
		<link>http://www.oncologyproductguide.com/blog/2008/02/29/novartis-kidney-cancer-drug-shows-promise/</link>
		<comments>http://www.oncologyproductguide.com/blog/2008/02/29/novartis-kidney-cancer-drug-shows-promise/#comments</comments>
		<pubDate>Fri, 29 Feb 2008 17:46:20 +0000</pubDate>
		<dc:creator>Melissa Chang</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Kidney Cancer]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Novartis AG]]></category>

		<guid isPermaLink="false">http://www.oncologyproductguide.com/blog/2008/02/29/novartis-kidney-cancer-drug-shows-promise/</guid>
		<description><![CDATA[Swiss company Novartis AG has reported that an independent data monitoring committee stopped a major trial of an investigational drug after interim results showed significantly better survival rates in kidney-cancer patients taking the therapy.Novartis was in Phase III of clinical trials, but the independent committee stopped the trial, involving some 400 patients in a dozen [...]]]></description>
			<content:encoded><![CDATA[<p><img border="1" vspace="2" align="left" width="147" src="http://www.oncologyproductguide.com/blog/wp-content/uploads/2008/02/novartis-logo.jpg" hspace="5" alt="Novartis logo" height="54" />Swiss company <a href="http://www.novartis.com/">Novartis AG</a> has reported that an independent data monitoring committee stopped a major trial of an investigational drug after interim results showed significantly better survival rates in kidney-cancer patients taking the therapy.Novartis was in Phase III of clinical trials, but the independent committee stopped the trial, involving some 400 patients in a dozen countries, because the study met its primary endpoint. Researchers say the targeted therapy could have promise for people with late-stage renal-cell cancer. Researchers are also evaluating the drug&#8217;s use in neuroendocrine tumors, lymphoma and other cancers.</p>
<p><a href="http://www.bizjournals.com/eastbay/stories/2008/02/25/daily65.html">Get the full story here.</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.oncologyproductguide.com/blog/2008/02/29/novartis-kidney-cancer-drug-shows-promise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
